Long-Acting/Extended Release (LA/ER) Antiretroviral Drugs Workshop: Current Status and Future Prospects - 2017

Sunday, February 12, 2017
Washington State Convention Center

    Carl Dieffenbach; Director, Division of AIDS, NIH    
    [video]  [audio-only/slide]

    Charles Flexner, Johns Hopkins University
    Where will we LEAP to next?!  Overview of Workshop
    [video]  [audio-only/slide]

    Peter Williams (Janssen)
    Current Status of Clinical Development of LA-Rilpivirine?
    [video/slides]  [audio-only/slide]

    Bill Spreen, (ViiV Healthcare)
    Current Status of Clinical Development of LA-Cabotegravir
    [video/slides]  [audio-only/slide]

    Susan Swindells, University of Nebraska Medical Center
    LEAP TB – Update from the LEAP Working Group on Development of Long-Acting Approaches to the Treatment of Tuberculosis
    [video/slides]  [audio-only/slide] 
    Marco Siccardi, University of Liverpool
    Update from the LEAP Modeling and Simulation Core: The use of Physiologically-based Pharmacokinetic
    and Pharmacodynamic Modelling to Assess Drug Candidates

    [video/slides]  [audio-only/slide]
    Richard Koup, Vaccine research Center, Division of AIDS
    LA-VRC01 – Development of a long-acting broadly neutralizing anti-HIV monoclonal antibody for parenteral administration
    [video/slides]  [audio-only/slide]
    Larry Corey, University of Washington
    Clinical development of broadly neutralizing monoclonal antibodies for HIV treatment and prevention
    [video/slides]  [audio-only/slide]

    Howard Gendelman, University of Nebraska
    [video/slides]  [audio-only/slide]

    Dirk Hair-Donald Loveday, Celanese Corporation
    Polymer chemistry as a platform for LA/ER drug delivery
    [video/slides]  [audio-only/slide]

    Nicolas Pacelli, Microchips Biotech
    Programmable Microchips
    [video/slides]  [audio-only/slide]

    Rahul Bakshi, Johns Hopkins University
    LATE BREAKER: Long-acting parenteral atovaquone nanoformulation for malaria prophylaxis
    [Presentation withheld at speaker's request, until further notice]
    Polly Clayden, Rapporteur
    To Inject or to Implant, That Is the Question
    [video/slides]  [audio-only/slide]
    Jeff Jacobson, Rapporteur
    What to do about the ‘Tail?’ Coverage for missed doses and regimen changes
    [video/slides]  [audio-only/slide]
    Susan Swindells, Rapporteur
    Resistance to LA/ER ARV drugs: What is the risk, and how can this be prevented? 
    [video/slides]  [audio-only/slide]